Sun Pharmaceutical Industries Ltd, leading specialty generics company, will acquire Organon at $14 per share in an all-cash transaction, valuing the company at an enterprise value of $11.75 billion, funded through internal accruals and borrowings. The transaction will be executed through a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the […]